---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-036587"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:41:07.121651+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MAIA enters into ATM agreement to sell up to $1.445M of common stock via H.C. Wainwright

## Summary
- ATM agreement with H.C. Wainwright to sell up to $1,445,000 of common stock.
- Wainwright will receive 3.0% commission on gross proceeds from each sale.
- Shares sold under existing effective shelf registration statement (Form S-3).
- Agreement terminates upon sale of all shares or by either party at any time.
- Company not obligated to sell any shares; may suspend solicitation at any time.

## SEC filing metadata
- accession: 0001193125-24-036587
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312524036587/0001193125-24-036587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312524036587/d756637d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-036587
- JSON: https://secwatch.observer/filing/0001193125-24-036587.json
- Plain text: https://secwatch.observer/filing/0001193125-24-036587.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $1,445,000 (effective 2024-02-14).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $1,445,000
  - Effective: 2024-02-14
  source text: On February 14, 2024, MAIA Biotechnology, Inc. (“we,” “us,” the “Company” or “MAIA”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), to sell shares of our common stock, par value $0.0001 per share, (the “Shares”) having an aggregate sales price of up to $1,445,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312524036587/0001193125-24-036587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.